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Abstract
The plaque reduction neutralization test (PRNT) is a confirmatory diagnostic assay that is used to
confirm a variety of diseases. The performance of PRNT requires the use of infectious wild type
viruses, which increases the risk of laboratory acquired infections. For instance, eastern equine
encephalitis (EEEV) is a highly virulent pathogen used in PRNT that can result in potentially
fatal neurological diseases among humans and equines. Therefore, arboviral PRNT must be
performed in Biosafety Level 3 (BSL-3) containment facilities and may require select agent
approved scientists, like in the case of EEEV. These stringent requirements restrict the ability of
public health laboratories to conduct PRNTs. Chimera viruses, recombinant constructs that have
been bio-engineered to express the immunogenic structural proteins from the wild type virus in
an attenuated form, can serve as a substitution for infectious viruses when performing PRNT.
Since chimera viruses do not require the use of a BSL-3 facility and are not classified as select
agents, their use offers advantages over wild type viruses. This study aimed at validating the use
of EEE and West Nile chimera viruses as an alternative to the corresponding wild type viruses
for diagnostic purposes at the Florida Department of Health (FDOH) Bureau of Public Health
Laboratories (BPHL). These evaluations were conducted using human and avian sera. The
results illustrate that chimera virus-based PRNT portrays specificity comparable to that of the
wild type virus, while a slight reduction in sensitivity was observed when human sera was used.
Considering their benefits in increasing safety and reducing regulatory requirements, these
chimera viruses are an important alternative to the virulent wild type viruses and could be highly
beneficial for diagnostic laboratories.

viii

Chapter One: Introduction
Arboviruses: Overview
Arboviruses are zoonotic viruses that are transmitted from an arthropod vector to a
vertebrate host (Go, Balasuriya, & Lee, 2014; Weaver & Reisen, 2010). Over 100 species of
arboviruses have been identified and they are transmitted to humans and other mammals by
infected, hematophagous female arthropod vectors, such as mosquitoes and ticks (LaBeaud,
Bashir, & King, 2011; Liang, Gao, & Gould, 2015; Weaver & Reisen, 2010).
Currently, arboviral diseases represent over 30% of all emerging infectious diseases. This
global representation is due to factors such as climate change, population increase, and
urbanization (Jones et al., 2008; Hollidge, Weiss, & Soldan, 2011; Liang, Gao, & Gould, 2015).
In regards to climate change, most vectors thrive in high climate temperatures (i.e. 80⁰F and
above); therefore, the majority of arboviruses that are associated with human and animal diseases
circulate within tropical and subtropical regions of the world (Liang, Gao, & Gould, 2015). For
example, countries in Southeast Asia (i.e. Japan and India), North, South, and Central America
(i.e. U.S., Brazil, and Costa Rica), Sub-Saharan Africa, the Caribbean, and the Mediterranean
have a high prevalence of arboviral infections transmitted by Culex spp and Aedes spp
mosquitoes (Gould & Solomon, 2008; Liang, Gao, & Gould, 2015; Patterson, Sammon, & Garg,
2016). In Florida, the hot temperature climate and long rainy seasons provide optimal breeding
conditions for mosquitoes (Adalja, Sell, Bouri, & Franco, 2012; Gargano et al., 2013).
Nevertheless, the geographical range in which arboviruses circulate has been and continues to be
extending beyond tropical and subtropical regions of the world (Go, Balasuriya, & Lee, 2014).
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Urbanization and increasing population have caused humans to encroach on mosquito
habitations which may increase the risk of transmission of arboviral infections (Go, Balasuriya,
& Lee, 2014; Gould & Solomon, 2008; Liang, Gao, & Gould, 2015).The increase in the
incidence of arboviral diseases may lead to increased cost associated with diagnosis,
surveillance, and treatment of arboviruses which may translate into a greater economic burden
(Barrett, 2014; Liang, Gao, & Gould, 2015). For example, since 1999, hospitalizations caused by
infections with West Nile Virus (WNV) cost approximately $800 million dollars in the U.S.
(Barrett, 2014).

Arboviruses: Classifications
Arboviruses consist of a large group of zoonotic viruses that infect arthropods. These
viruses are typically classified into the Togaviridae family, Flaviviridae family, Bunyaviridae
family, and Reoviridae family (Atkins, 2013; Beckham & Tyler, 2016; Hollidge, Weiss, &
Soldan, 2011). For the interest of this study, only the Togaviridae and Flaviviridae family will be
described.
The Togaviridae has a genome that ranges from 7 to 11.8 kb in length, is non-segmented,
and contains positive sense-single stranded RNA (Garmashova et al., 2007). This family consists
of the Rubivirus and Alphavirus genera, only the latter contains arboviruses. Alphaviruses are
small enveloped RNA viruses that contain two open reading frames (ORF) within their genome
(Atkins, 2013; Hollidge, Gonzalez-Scarano, & Soldan, 2010; Martinez, Snapp, Perumal,
Macaluso, & Kielian, 2014). The Alphavirus genus contains 26 arboviruses (Powers et al, 2001).
There are 29 known alphaviruses that are transmitted worldwide that include, but are not limited
to, eastern equine encephalitis virus (EEEV), western equine encephalitis virus (WEEV),

2

venezuelan equine enecphalitis virus (VEEV), Sindbis virus (SINV), and chikungunya virus
(CHIKV, Hollidge, Gonzalez-Scarano, & Soldan, 2010).
The Flaviviridae family consists of the Flavivirus genus. This genus contains over 75
identified arboviruses of which approximately 40% are mosquito-borne, while 16 are tick-borne,
and the remaining 18 have no known vectors (Heinz et al., 2000; Hollidge, Gonzalez-Scarano, &
Soldan, 2010;). Flaviviruses are positive sense single stranded enveloped RNA viruses that are
spherical in shape (Yu et al., 2008). Their non-segmented genome generates ten mature viral
proteins by the proteolytic processing of a single polyprotein (Stadler et al., 1997). The viral
proteins include three structural proteins that consist of a capsid, envelope, premembrane, and
seven nonstructural proteins. This genus contains more than five of the most well-studied
encephalitis-causing arboviruses which include WNV, St. Louis encephalitis virus (SLEV), La
Crosse encephalitis virus (LACV), and Japanese encephalitis virus (JEV, Atkins, 2013; Hollidge,
Gonzalez-Scarano, & Soldan, 2010).

Arbovirus: Prevention
Preventative control measures are the best method of protection against arboviral
infections. Suggested mosquito control measures include: wearing protective clothing such as
long pants and long sleeved-shirts, using bed nets, avoiding outside activities during hours when
mosquitos are most active, staying in air-conditioned environments, and using mosquito
repellants (Center for Disease Control and Prevention, 2016; Florida Department of Health,
2017).
Alphavirus: Eastern Equine Encephalitis
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Overview. Eastern equine encephalitis virus (EEEV) was first discovered in 1831 when
75 horses mysteriously died of viral encephalitis in Massachusetts (Morris, Callahan, & Howard,
1988). In humans, EEE has a morbidity rate of approximately 90% and a mortality rate of 3075%, especially in those over the age of 50 and under the age of 15 (Armstrong & Andreadis,
2013; Zacks & Paessler, 2010). There have been a total of 270 human cases of EEE reported
from 1964 to 2010 (Hollidge, Gonzalez-Scarano, & Soldan, 2010).
The genome of EEEV is approximately 11.7kb in length, which includes a 5’cap and a 3’
poly (A) tail. The 5’ end of the genome encodes for four nonstructural proteins, NSP1 to NSP4
(Young et a., 2008). The 3’ end of the genome encodes a sub-genomic RNA (26S) that produces
three main structural proteins which include a capsid and envelope glycoproteins E1 and E2
(Arrigo, Adams, & Weaver, 2010; Weaver et al., 1994).
Originally, the virus was divided into two strains, North and South American, based on
their antigenic properties. However, additional antigenic and phylogenetic analyses have
reclassified the virus to include four subtypes that correspond to four major genetic lineages,
named lineages I to IV (Arrigo, Adams, & Weaver, 2010; Atkins, 2013). The North American
EEEV strains and several of the Caribbean strains consist of lineage I, whereas the South and
Central American EEEV strains comprise lineages II to IV (Beckham & Tyler, 2016; Brault et
al., 1999). Lineages II to IV have become a separate viral species known as the Madariaga virus
(Weaver et al., 1994).
Life Cycle. Transmission of EEEV occurs when an infected female mosquito takes a
blood meal from an avian host and transmits EEEV (Figure 1). Culiseta melanura and Culiseta
morsitans are the predominant vectors that transmit EEEV to the avian host (Atkins, 2013;
Morris, Callahan, & Howard, 1988; Vander Kelen, Downs, Stark, Loraamm, Anderson, &
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Unnasch, 2012; Zacks & Paessler, 2010). Other mosquito species such as Aedes vexans,
Coquillettidia petrubans, Ochlerotatus Canadensis, and Oc. sollicitans, among others, have been
implicated as epizootic bridge vectors from viremic birds to equines, domesticated animals, and
humans (Armstrong & Andreadis, 2008, 2010; Cupp, Klinger, Hassan, Viguers, & Unnasch,
2003; Morris, Callahan, & Howard, 1988; Vander Kelen, Downs, Stark, Loraamm, Anderson, &
Unnasch, 2012). Eastern equine encephalitis virus is known to replicate at the site of infection,
typically in non-neural tissues such as the lymphatic system or tissue adjacent to the mosquito
bite (Arrigo, Adams, & Weaver, 2010; Jose, Snyder, & Kuhn, 2009). Post-transmission to a
mammalian host, EEEV enters through the host subcutaneous and cutaneous tissues through
cellular receptors (Strauss, Rumenapf, Weir, Kuhn, Wang, & Strauss, 1994). The virus, then,
migrates to the lymph nodes where it reaches the bloodstream. In the bloodstream, EEEV binds
to specific tissue receptors, undergoes endocytosis and initiates an RNA-dependent synthesis as
well as protein synthesis (Jose, Synder, Kuhn, 2009; Strauss, Rumenapf, Weir, Kuhn, Wang, &
Strauss, 1994).
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Figure 1. This figure shows the transmission cycle of Eastern Equine Encephalitis virus. Source:
Cornell University, College of Veterinary Medicine (2017, November). Eastern Equine
Encephalitis.

Symptoms. Infection with EEEV can either be systemic or encephalitic (Armstrong &
Andreadis, 2013). Occasionally, those who become infected with EEEV may be asymptomatic
(Deresiewicz, Thaler, Hsu, & Zamani, 1997). The incubation period for EEEV is 4 to 10 days in
humans and 5 to 14 days in equines (Armstrong & Andreadis, 2013; Zacks & Paessler, 2010).
Clinical manifestations of a systemic infection typically occur abruptly and include fevers,
abdominal pain, chills, arthralgia, weakness, headache, and myalgia (Deresiewicz, Thaler, Hsu,
& Zamani, 1997; Heymann, 2015). The prodrome has a duration lasting one to two weeks and
recovery is complete when there is no sign of central nervous system involvement (CDC, 2016a).
An estimated 35% of those who survive are left with disabling and progressive mental and
physical sequelae, with neurological symptoms ranging from minimal brain dysfunction to
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severe intellectual dysfunction (Vander Kelen, Downs, Stark, Loraamm, Anderson, & Unnasch,
2012).
Diagnosis and Treatment. Diagnosing EEEV infection can be difficult due to the
similarities that are shared among other encephalitic infections such as LaCrosse virus,
tuberculosis, coxsackieviruses, naegleria infection, legionnaires disease, and rabies (Gaensbauer,
Lindsey, Messacar, Staples, & Fischer, 2014). Unfortunately, there is no readily available cure
or vaccine for humans against EEEV. Treatment consists only of supportive care (Gaensbauer,
Lindsey, Messacar, Staples, & Fischer, 2014; Heymann, 2015).

However, there are three

vaccines available for equines (United States Department of Agriculture, Animal Plant Health
Inspection Service, 2008). The vaccines are monovalent, bivalent, and trivalent. Owners of
horses are recommended to scrutinize which vaccine is best to use depending on the local
prevalence of the disease (FDOH, 2017; USDA, APHIS, 2008).
Future Research. EEEV will continue to remain a public health concern. Currently,
researchers are working on human vaccines for EEEV infection. Investigation EEEV vaccines
and for other alphaviruses (i.e. Venezuelan equine encephalitis) may become available for people
who are at high risk for infection; however availability will be limited (FDOH, 2017; Heymann,
2015).

Flavivirus: West Nile Virus
Overview. West Nile virus (WNV) is one of the earliest recognized arthropod-borne viral
diseases of man (Gubler, 2007). It was first isolated in 1937 in the homonymous province of
Uganda from the blood of a febrile woman (Briese et al., 1999; Gubler, 2007; Kramer, Li, & Shi,
2007). Between 1999 and 2014 there have been 41,762 human cases (inclusive to 18, 810
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neruoinvasive cases) of WN disease that have been reported to the CDC (National Institute of
Health, 2015). In 2014, there were 2,205 cases and in 2015 there were 2,060 cases (Donadieu et
al., 2013).
The genome of WNV is approximately 11kb in length and encodes for three structural
proteins (capsid, pre-membrane, and envelope) and seven nonstructural proteins (Castle, Nowak,
& Wengler, 1985). The capsid protein is associated with the genome to form the nucleocapsid
which is also enclosed by a lipid bilayer with E proteins protruding outward (Castle, Nowak,
Wengler, & Wengler, 1986). The E proteins facilitate cellular attachment and membrane fusion
and are a significant virulence factor (Marfin & Gubler, 2001).
There are two genetic lineages of WNV; Lineage 1 consists of isolated strains from
Europe, Middle East, South Asia, North America, some African strains, and Australia (Chancey,
Grinev, Volkova, & Rios, 2014). This lineage entails the strains that have caused encephalitic
outbreaks among humans and horses (Jia et al., 1999). Lineage 2 is comprised of southern Africa
strains, central Africa, and the original Ugandan strain isolated in 1937 (Komar, 2003). Theses
genetic lineages continually occur and are maintained in nature by a WNV primary host (Paz,
2015).
Life Cycle. West Nile virus is typically transmitted by Culex spp mosquitoes. However,
it can also be transmitted via Aedes and Anopheles (Hayes et al., 2005). Culex tarsailis is the
primary mosquito vector of WNV in the western regions of the United States (Colpitts, Conway,
Montgomery, and Fikrig, 2012). West Nile virus is maintained in animal hosts; preferably birds
in the Corvidae family i.e. blue jays and crows by mosquitoes (Figure 2, Hayes et al., 2005).
Equines and humans can acquire WNV as dead-end or incidental hosts (Chancey, Grinev,
Volkova, & Rios, 2014). West Nile virus is known to replicate at the site of infection. After a
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mosquito takes a blood meal from an infected human host, the virus enters through the skin cells
through cellular receptors (Gyure, 2009; Lim, Koraka, Osterhaus, & Martina, 2011). This
enables the virus to migrate to the lymph nodes and then into the bloodstream (Cho & Diamond,
2012; Klein & Diamond, 2008). Viral entry of the central nervous system follows activation of
toll-like receptors and tumor necrosis factor-α which increases the permeability of the virus
crossing the blood-brain barrier (Cho & Diamond, 2012; Klein & Diamond, 2008; Samuel &
Diamond, 2006). West Nile virus directly infects neurons within the deep nuclei and gray matter
area of the brain, brainstem, and spinal cord (Hayes, Sejavrt, Lanicotti, Bode, & Campbell 2005;
Sitati & Diamond, 2006).
Symptoms. Approximately 80% of human infections with WNV are asymptomatic.
Symptoms can range from flu-like malaise to severe neuroinvasive disease (Paz, 2015). Less
than 1% of human infections progress to severe WN disease (Chancey, Grinev, Volkova & Rios,
2014). Seroepidemiological studies have demonstrated that 20-25% of WNV infected individuals
develop mild illness and about 0.67% develop WN neurological disease (Beckham & Tyler,
2016; Chancey, Grinev, Volkova & Rios, 2014; Hayes et al., 2005). Neurological cases
frequently consist of meningoencephalitis (Komar, 2003). Encephalitis is only one of several
severe symptoms caused by WNV. The incubation period for WNV in humans is between 2 and
14 days. (Hayes et al., 2005; Petersen & Marfin, 2002). Though infections are subclinical and
often asymptomatic, occasionally clinical manifestations develop 2 to 21 days post infection
(Hayes et al., 2005; Petersen & Roehrig; 2001). Cases where neurological symptoms do not
develop and patients are not hospitalized are referred to as WN fever (Komar, 2003).
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Figure 2. This figure shows the transmission cycle of West Nile virus. Source: Paxtang
Borough:Harrisburg, PA. (2017, November).

Diagnosis and Treatment. Diagnosis of WNV infection can be challenging due to the
clinical similarities the virus shares with other infectious agents such as EEEV and SLEV
(Hollidge, Gonzalez-Scarano, & Soldan, 2010). WNV-related meningitis and encephalitis are
clinically indistinguishable from meningitis and encephalitis related to other viral diseases.
Movement disorders such as Parkinson’s disease and poliomyelitis share similar pathogenesis
with WNV encephalitis (Komar, 2003). West Nile virus can also be associated with GuillainBarre syndrome and radiculopathy (Gyure, 2009; Petersen & Marfin, 2002).
Unfortunately, there is no vaccine and there are no specific antiviral treatments for WNV
infections (NIH, 2015). Over-the-counter pain relievers can be used to mitigate WN disease
symptoms (Chancey, Grinev, Volkova & Rios, 2014; Komar, 2003). For cases that require
10

hospitalization, supportive treatment such as intravenous fluids can be administered (CDC,
2016b).
Future Research. Research focusing on vector control strategies such as reducing the
abundance of mosquitoes, developing more effective repellent, and understanding mosquito
behavior needs to continue (Hayes et al., 2005; Petersen & Roehrig, 2001). In addition, the
development of a vaccine for WNV is highly needed. There is a NIH-funded trial for a vaccine
that is known as HydroVax-001 (NIH, 2015). HydroVax-001 is a hydrogen peroxide-based
technique that causes the WNV to be inactive while maintaining the triggering surface structure
of the immune-system (NIH, 2015).
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Chapter Two: Laboratory Diagnostic Techniques
Neutralization
Plaque Assays. Plaque assays are one of the most widely practiced techniques that are
used to measure the ability of multiple infectious virions to form a plaque (i.e. a group of
infected cell) on a confluent monolayer of cultured cells (Shurtleff et al., 2012). These assays are
used for virus isolation, purification of viral clonal populations, and determining the titer of
viruses (Baer & Kehn-Hall, 2014; Juarez, Long, Aguilar, Kochel, & Halsey, 2013).
Plaque Reduction Neutralization Test. Plaque reduction neutralization test (PRNT) is a
commonly used type of plaque assay that is implemented worldwide for diagnostic purposes.
This test is considered to be the gold standard for detecting and measuring antibodies that can
neutralize viruses because it has a higher sensitivity than other tests (i.e. hemagglutination
inhibition and enzyme-linked immunosorbent assay) without compromising specificity (Baer &
Kehn-Hall, 2014; Gennaro, Lorusso, Casaccia, Conte, Monaco, & Savini, 2014). A fixed amount
of viral suspension is added to serum dilutions of each sample (Juarez, Long, Aguilar, Kochel, &
Halsey, 2013). The viral-serum mixture is then incubated to allow the antibodies, if present in the
subject sample, to attach to and neutralize the virus (Dulbecco & Vogt, 1953). The mixture is
then added to a monolayer of confluent cells (Shurtleff, Keuhne, Biggins, & Keeney, 2011). An
agarose mixture is placed onto the cells to limit the virus from spreading indiscriminately (Klebe
& Harriss, 1984). The cells are incubated for one to four days to allow for viral growth and the
formation of plaques. The plaques are counted using a vital dye such as neutral red (Shurtleff et
al., 2012). Viral titers are measured in plaque forming units (PFU) per milliliter and are
calculated by taking the reciprocal of the highest serum dilution that can reduce the number of
12

plaques by 90% compared to the serum free virus (Baer & Kehn-Hall, 2014; BD Biosciences,
2017; CDC, 2016c; Martrosovich, Martosovich, Garten, & Klenk, 2006; Mckeating, 1991).
Multiple virions could potentially infect a single cell, therefore the term plaque forming
unit (PFU) is used (CDC/DVBD, 2017; Martrosovich, Martosovich, Garten, & Klenk, 2006).
Plaque morphology such as plaque size, border definition, clarity, and distribution provide
valuable information concerning the growth and virulence factors of the virus (Abedon & Yin,
2009). However, the morphology of the plaques are heavily impacted by the growth conditions
of the cells (Abedon & Yin, 2009; Baer & Kehn-Hall, 2014).
Use of Wild Type Viruses. Performance of arboviral PRNT requires the use of a Biosafety
Level 3 (BSL-3) containment facility when working with risk group 3 biological agents such as
EEEV and WNV are used (Komar, Langevin, & Monath, 2009). These agents possess the
capability of causing severe human disease (i.e. encephalitis), therefore, if exposed laboratory
personnel are at an increased for acquiring an infection because there is no curative treatment
available (American Biological Safety Association, 1988; Coelho & García Díez, 2015; Johnson
et al., 2011; Public Health Agency of Canada, 2009; Tun, Sadler, & Tam, 2006; World Health
Organization, 2003).
Training. Manipulation of risk group 3 agents within a BSL-3 facility requires extensive
training and clearances, several layers of personal protective equipment (PPE), and various
background checks (ABSA, 1988; Johnson et al., 2011; Tun, Sadler, & Tam, 2006).
Furthermore, use of select agents (i.e. EEEV) requires laboratorians to be select agent approved
by the Federal Select Agent Program, under the CDC. According to the Select Agent Program,
each laboratory must have a limited number of select agent approved personnel that can be
trained (Bureau of Public Health Laboratories, 2015). Additionally, there are a finite number of
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public health labs that are equipped with a BSL-3, much less enrolled in a Select Agent program
(Johnson et al., 2011).
According to the CDC Biosafety in Microbiological and Biomedical Laboratories
(BMBL, 5th Ed., 2009), a BSL-3 facility is used to perform diagnostic, clinical, teaching, or
research with exotic or indigenous agents that may cause a serious or potentially lethal disease
through the transmission route of inhalation due to exposure. All laboratory personnel are
required to receive specialized training to handle such pathogens (ABSA, 1988; Tun, Sadler, &
Tam, 2006). The laboratorians must be supervised by a scientist who is familiar with the
associated procedures and is competent in handling infectious agents (Fleming, 1995; WHO,
2004). All procedures that incorporate the manipulation of potentially infectious materials must
be conducted within a class II or class III biosafety cabinet (WHO, 2004).
At the Tampa Bureau of Public Health Laboratory (BPHL), all personnel must wear PPE
that is in compliance with the BMBL. Specifically, there are two types of PPE that a laboratorian
can choose to wear (ABSA, 1988; Tun, Sadler, & Tam, 2006; WHO, 2004). One consists of
using an N-95 respirator and the other entails the usage of a powered air respirator (PAPR).
Laboratorians that choose to work with the N-95 respirators are subject to fatigue, physical and
mental exhaustion, and a reduction in efficiency (Tun, Sadler, & Tam, 2006). However, with the
N-95 respirator, peripheral vision is not distorted and flexibility and adequate range in motion is
allowed (Fleming, 1995; WHO, 2003). Whereas the PAPR, reduces the peripheral vision of the
users, thus creating opportunities for error, spills, and other mistakes to occur (WHO, 2004).
However, the PAPR reduces the facial stress that the N-95 causes (Tun, Sadler, & Tam, 2006).
Due to these conditions, it is highly recommended that laboratorians use the buddy system and
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not work alone (BPHL, 2015). Thus, these conditions create an ineffective and unsafe work
environment for laboratorians (Tun, Sadler, & Tam, 2006).
Laboratory acquired infections. In spite of all of the necessary precautions, protocols,
and procedures that are in place, accidents and laboratory acquired infections (LAIs) can still
occur (Fleming, 1995; Pike 1976; Sewel, 2006;). Approximately, 45% of clinical diagnostic
laboratories account for the total number of LAIs (CDC, 2009; Sewell, 1995). Overall, there has
been an increase of cases that have been reported regarding laboratory acquired infections, most
of which involve microbiological agents belonging to risk group 3 (Fleming, 1995; Pike, 1979;
Sewell, 2006; WHO, 2004).
According to Nagata, Wong, Wu & Hu (2013), four laboratory acquired-cases of EEEV
and sixteen cases of WEEV were documented, with four of the sixteen cases resulting in fatality.
Primary hazards that can result in an accidental EEEV inoculation include viral contact with
broken skin or mucous membranes, bites from infected mosquitoes or rodents within the
laboratory (Fleming 1995, Pike, 1979; PHAC, 2010; Sewel, 1995). Another arbovirus that has
caused several LAIs is WNV. In 2002, the CDC reported two cases of WNV infection in
laboratory workers, both were microbiologists, without other known risk factors who acquired
the infection through percutaneous inoculation. Since then, over 20 West Nile virus- laboratory
acquired infections have occurred (CDC, 2002).
Capacity. Select agents, such as wild type EEEV, require classified Health and Human
Services (HHS) and USDA select agent BSL-3 containment facilities (Johnson, Kosoy,
Hunsperger, Beltran, Delorey, Guirakhoo, & Monath, 2009). This prevents public health
laboratories that are only equipped with BSL-2 facilities and laboratories that have non-select
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agent approved personnel from confirming arboviral infections via PRNT (Johnson et al., 2011;
Komar, Langevin, & Monath, 2009).
Turnaround Time. Typically, PRNT takes one to two weeks to complete; however, this
varies depending on the virus that is being confirmed. Wild type viruses, especially flaviviruses,
grow very slowly and tend to produce small sized plaques (Gennaro, Lorusso, Casaccia, Conte,
Monaco, & Savini, 2014). Due to length of time required to complete a PRNT assay, turnaround
times for diagnostic purposes are increased (BPHL, 2015). The increased turnaround time
imposes a critical, and in some cases detrimental, dilemma for those who are waiting on the
diagnostic results in order to make an important medical decision (Rabe et al., 2016). This factor
had a significant impact on the pregnant women who were waiting on confirmatory PRNT
results for Zika virus to determine if their pregnancy should be terminated or not (Bingham et al.,
2016; Rabe et al., 2016).
Chimera Viruses. As explained earlier, performance of PRNT using pathogenic wild
type viruses places laboratory personnel at an increased risk for laboratory acquired infections,
increases turnaround time, and decreases the capacity for public health laboratories to confirm
arboviral diagnosis via PRNT (Johnson et al., 2011). Chimera viruses are a safer alternative
because they decrease the risk of obtaining an infection, decrease turnaround time, and increase
capacity for confirmatory diagnostics within public health laboratories (Johnson et al., 2011;
Komar, Langevin, & Monath, 2009; Monath, 2011). Moreover, chimera viruses have
demonstrated to produce phenotypically larger plaque sizes that are more definitive to see and
count which provide a more accurate titer reading (Johnson et al., 2009).
Chimera viruses are recombinant viruses consisting of a mixture of genes from two or
more different viruses constructed from cDNA clones that encode a complete RNA viral genome
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(CDC, 2009). Chimeric viruses are composed of the genes and gene products responsible for
intracellular replication belonging to the vaccine or attenuated virus and the genes and gene
products of the envelope of the virus of interest (Monath, 2001). Since the viral envelope
contains all of the antigenic determinants responsible for inducing neutralizing antibodies, the
result of infection with the chimeric virus is that such antibodies are generated only against the
second virus and will not produce an immunogenic response (Monath, 2001). Chimera viruses
possess the equivalent antigenic makeup that will provide comparable sensitivity and specificity
to the wild type viruses in the assay (Komar, Langevin, & Monath, 2009). Therefore, chimera
viruses should have the capability of being neutralized by antibodies that are elicited during
infections of the wild type virus (Johnson et al., 2011).
There are several full-length viruses or truncated replicons that have been bio-engineered
from numerous flaviviruses and alphaviruses to produce chimeras. Chimera flaviviruses are
constructed from an attenuated yellow fever vaccine virus backbone that is combined with
structural protein genes replaced with heterologous virus (Monath, 2001, 2011). Chimera
alphaviruses are constructed from a Sindbis virus (a relatively non-pathogenic human alpha
virus) backbone that is combined with structural protein genes replaced with heterologous virus
(Johnson et al., 2011).
These safe alternatives may be used under BSL-2 containment facilities and practices
(Komar, Langevin, & Monath, 2009). Validation of chimera viruses can enhance the capacity in
which public health laboratories with limited facilities and Select-Agent approved personnel can
perform confirmatory arbovirus diagnostic testing (Johnson et al., 2011). Additionally, use of
chimera viruses can also decrease the turnaround times of the patient results because chimeras
tend to grow faster than their wild type counterparts (Johnson et al., 2009, Johnson et al., 2011;
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Monath, 2011). Plaque reduction neutralization test using chimera viruses allow results to be
analyzed within one to two days post inoculation, which drastically reduces the turnaround time
from 3-14 days to 2-7 days (Gennaro, Lorusso, Casaccia, Conte, Monaco, & Savini, 2014). A
reduction in turnaround times creates the opportunity for timely medical decision to occur and
recommendations for prevention, such as mosquito control for the circulating viruses (Johnson et
al., 2011). Moreover, chimera viruses have demonstrated to produce phenotypically larger
plaque sizes that are more definitive to see and count which provide a more accurate titer reading
(Johnson et al., 2009). Although, the chimera virus will not elicit a replicable response as the
wild type, the alternative responses are comparably sufficient to determine the serostatus in
serological diagnostic testing (Johnson et al., 2011). Overall, chimera viruses are an important
and beneficial asset for the purpose of laboratory diagnostics. Their usage in PRNT diagnostics
is invaluable.

Rationale of the Study
Therefore, the purpose of this study was to evaluate EEE and WN chimera viruses in the
PRNT assay. These chimera viruses are a safer alternative to the wild type pathogen counterparts
because they are non-pathogenic to humans while still maintaining antigenicity. Additionally,
chimera viruses enhance the capacity of public health laboratories to perform arboviral
confirmation tests such as PRNT.
The specific aims of this study were to: 1) assess the serostatus outcomes, sensitivity, and
specificity of each chimeric virus and 2) to assess the titer agreement of each chimeric viruses
used at the Bureau of Public Health Laboratory (Tampa). Successful completion of this study
provides an assessment on the performance of chimeric viruses using different specimen sources
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and provides another perspective on performing PRNT overall. Currently, all EEEV and human
clinical WNV PRNT testing was performed using wild type viruses for the state of Florida is
performed at the Bureau of Public Health Laboratories.
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Chapter Three: Materials and Methods
Media. The following reagents were used to make the media and diluent. Bovine Serum
Albuminin (BSA) was purchased from Millipore®, Fetal Calf Serum (FCS) was purchased from
Hyclone Fischer®, Dulbecco’s Modified Eagle’s Medium (DMEM), , Hepes, glutamine
(essential amino acids), fungizone (antifungal), kanamycin (antibiotic) , penicillin (antibiotic),
and streptomycin (antibiotic) were all purchased from Gibco®. The following reagents were used
to make the media-agar solution for the first and second overlays in PRNT. Sea Kem Agarose,
Sodium Bicarbonate powder, and Neutral red stock solution were purchased from Fischer®.
Viruses. The arboviruses that were used in this study consisted of WNV and EEEV. Eastern
Equine Encephalitis Virus strain D64-837 Vero 134 was derived from a patient specimen and
was cultured and grown at BPHL-Tampa. SINV/EEEV (North American strain) chimera virus
strain number 796 was obtained from the CDC that initially obtained the chimera from the
University of Texas Medical Branch, Galveston, Texas (Goodman et al., 2015). West Nile virus
strain NY99 Vero 136 was derived from a patient specimen and was cultured and grown at
BPHL-Tampa. The Yellow Fever/West Nile ChimeriVax® was obtained from the CDC who
initially obtained the chimera from Sanofi Pasteur.
Cells. Vero cells were initially obtained from ATCC® CCL-81TM; however, they were then
provided by the CDC. Vero cell are culturally maintained at BPHL-Tampa.
Viral Titration. A virus titration was performed for each virus in order to determine the Tissue
Culture Infectious Dose, TCID50/100 µl. All viral titrations were performed in BD Falcon Tissue
Culture © 6-well plates using Vero cells. Vero cells were approximately 90% confluent prior to
inoculation. A series of 14 serial virus dilutions were made using 100 ml of serum virus diluent
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(SVD) with 8% FCS. The first four viral dilutions were made at a 1:10 dilution, while the
remaining nine were half log dilutions. A total of 150 µl of each viral dilution were placed into a
96-well BD Falcon Tissue Culture

©

plate on top of a coated layer of 150 µl of SVD. The 96-

well plate was placed into a humidified chamber and incubated overnight at 4°C. After
incubation, media from the 6-well plates was aspirated until approximately 100 µl remained in
each well. Following the aspiration, 100 µl of the virus/diluent mixture was added in duplicate.
The plates were incubated at 37°C for 1 hour in a 5% CO2 incubator and rocked every 15
minutes. An overlay of media containing 0.5 ml of each antibiotic, 200mM glutamine, 1x
Eagle’s Minimum Essential Media (EMEM), 8% FCS, 1% hepes, 8.8% sodium bicarbonate, and
0.5% agar was placed onto the Vero plates, allowed to harden, and placed into a 37°C incubator.
After two and four day incubation for EEEV and WNV, respectively, a second overlay media
containing 2% of neutral red was placed onto the plates. The plaques were counted on days one
and two post second overlay. The dilution containing plaques ranging from 30-100 PFU was
chosen as the challenge viral dilution (CDC/DVBD, 2017).
Cell Culture. Vero cells were seeded to be confluent on the day the plates were used for PRNT.
BD Falcon Tissue Culture

©

6-well plates were used for avian sera samples and 12-well plates

were used for human sera samples. The seeding densities ranged from 7.5 to 10 x 10 4. The cells
were seeded within this range to ensure that cells were at minimum 90% confluent within 72
hours after seeding (CDC/DVBD, 2017). Cells were incubated at 5% CO2 and 37°C. The cells
were maintained in DMEM with 8% FCS, 1% sodium pyruvate, 3% sodium bicarbonate, and 0.5
ml of antibiotics at 37°C in a 5% CO2 incubator.
Serum Specimens. Avian and human sera were obtained from the FDOH BPHL-Tampa. Avian
sera samples that were tested for EEEV antibodies were obtained weekly from the Florida
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Sentinel Chicken Program from January 2016 to December 2016. All samples were initially
screened for EEEV and SLEV antibodies using the hemagglutination inhibition assay (HAI).
Samples with a titer of 10 or greater in HAI were then screened using enzyme-linked
immunosorbent assay (ELISA). For EEEV, the avian samples were selected based on their
Positive over Negative (P/N) value in ELISA and on their available volume. Specimens with a
(P/N) value greater than or equal to 5.00 and a volume of at least 300 µl were selected for PRNT.
Thirty samples (20 positive and 10 negative) were selected for this study because the
Center for Medicare & Medicaid Services (CMS) agency through Clinical Laboratory
Improvement Amendent (CLIA) recommends that a minimum of 20 samples should be used to
validate an assay (Association of Public Health Laboratories, 2013). Additionally, a sample size
of 30 improved the statistical power for this study. Previous PRNT results were blinded to the
technician performing PRNT prior to the beginning of the study.
Human sera samples that were tested for EEEV and WNV antibodies were obtained from
different Florida County Health Departments or hospitals and were submitted for diagnostic
arbovirus testing. Human sera samples were selected based on their original strength in IgG
ELISA for EEEV and WNV antibodies. Volume and P/N value selection criteria were the same
as the ones for avian samples. Human sera samples used for the EEEV studies were collected
between January 2003 to December, 2010. Twenty-two samples were pre-selected, of which 10
were negative. Due to the low quantity of clinical EEEV antibody positive serum samples,
contrived samples were created by making a 1:2 dilution containing negative alphaviral antibody
serum (positive flaviviral antibody serum) as the diluent. Therefore, a total of 20 presumptive
positive EEEV antibodies (10 original presumptive positive and 10 contrived samples) and 10
negative (flaviviral antibody positive) sera samples were used for this segment of the validation.
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The human serum samples for WNV antibodies were obtained from January, 2015 to
December, 2016. Thirty-eight human samples were pre-selected. Out of these 38 human serum
samples, 20 positive samples met the P/N criterion and a total of 10 negative samples met the
volume requirement. All human samples were initially stored in -80°C freezers, however, upon
use, samples were maintained at 2-8°C. All avian samples were stored at 2-8°C.
Plaque Reduction Neutralization Test. Plaque reduction neutralization test was used to
quantify the titer of neutralizing antibodies for a virus with the purpose of diagnosing infections.
All PRNT assays were performed at BPHL-Tampa. Neutralization assays for human sera
samples were performed in a 12-well plate according to CDC/DVBD standard protocol.
Neutralization assays for avian samples were performed in a 6-well plate according to standard
BPHL protocol.
Each sample was simultaneously tested with the wild type virus and the corresponding
chimera virus, for EEEV and WNV. Samples were diluted 1:5, with the diluent being SVD
supplemented with 8% FCS and then heat inactivated at 56°C for 30 minutes to destroy any
complement and to inactivate viruses. Samples then were serially diluted (i.e. two-fold) twelve
times for human sera and three times for avian sera in a 96-well Tissue Culture Falcon plate to
achieve endpoint 90% neutralization titers (CDC/DVBD, 2017; Rabe et al., 2016). The range in
titers for human sera using EEEV and WNV was 1:10 to 1:20480, with the lowest titer being
1:10. The titers for avian sera were 1:10 to 1:40. The viral challenge dilution was placed onto the
serially diluted sera samples, creating a final dilution of 1:2. The viral-serum mixtures were
incubated overnight at 4°C or for 1 hour at 37°C in a 5% CO2 incubator. Following incubation,
media was aspirated from the culture plates and 100 µl of the viral-serum mixture was inoculated
onto the monolayer of Vero cells. The plates then were incubated at 37°C in a 5% CO2 incubator
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for one hour and rocked every 15 minutes. An overlay of media containing supplemented
EMEM (as described above) was placed onto the Vero cell, allowed to harden, and placed into
the incubator. A second overlay media containing 2% of neutral red was placed onto the plates
two to four days post the first overlay for EEEV and WNV, respectively. The plaques then were
counted by hand and recorded for two days after the second overlay. Titer wells that contained
too many plaques were considered too numerous to count (TNTC). For each PRNT, a back titer
was run to ensure that the viral concentrations for both the wild type and chimera viruses were
appropriate and met the 200 plaque challenge, which is a control that was established to measure
the parameters of the assay (CDC/DVBD, 2017). Neutralizing antibody titers were calculated as
the reciprocal of the highest serum dilution that reduced the virus plaque count by 90% for
human sera samples (Johnson et al., 2011; Rabe et al., 2016). Avian sera samples used a 95%
reduction in order to compensate for the low volume of sera sample given. A PRNT 90 titer of 10
or greater was considered positive. Specimens were tested once, unless noted otherwise.
Statistical analyses. A nonparametric test of Cohen’s kappa was used to assess the level of
agreement between positive and negative results of the wild type and the chimera virus (Johnson
et al., 2011). A contingency table of the binary serostatus results was used to determine the
sensitivity and specificity of each chimera virus using the wild type virus-based PRNT as the
gold standard (Komar, Langevin, & Monath, 2009). This answers the research question of
whether the chimera viruses are an efficient alternative to the wild type viruses (Johnson et al.,
2011; Komar, Langevin, & Monath, 2009). Wilcoxon Signed Rank Test and kappa statistics was
used to assess the level of agreement between the positive titer results obtained from the wild
type virus and the chimera virus (Gennaro, Lorusso, Casaccia, Conte, Monaco, & Savini, 2014).
This answers the research question of whether the chimera virus yields similar titers to the
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corresponding wild type virus (Gennaro, Lorusso, Casaccia, Conte, Monaco, & Savini, 2014;
Johnson et al., 2011). The kappa statistical interpretations are as follows: a value of less than
0.20 is a poor agreement, 0.21 to 0.40 is a fair agreement, 0.41 to 0.60 is a moderate agreement,
0.61 to 0.80 is a good agreement, and 0.81 to 1.00 is a very good or excellent agreement
(McHugh, 2012). A ratio containing the obtained kappa values for avian to human serum
samples were calculated to illustrate the variations of titer agreements between the two specimen
sources. Additionally, a Pearson’s r correlation statistics was performed to demonstrate the
overall degree of association among titers. The level of significance was set to alpha (α) at 0.05.
All of the statistical analyses were performed using SPSS version 23.
Ethical Considerations. For this study, no patient contact was needed and samples were deidentified and no personal identifiers were recorded. The Department of Health protects the
confidentiality of all persons who may have had arboviral diseases (Ch.381.0055, F.S.; BPHL,
2014). This study was approved by both the USF IRB (Pro00031338) and the DOH IRB
(0004682).
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Chapter Four: Results
Eastern Equine Encephalitis PRNT
Serostatus of Avian Samples. Analyses of the avian sera test for EEEV antibodies
demonstrated that both the wild type and chimera challenge virus were neutralized by antibodies
present in the sera two to three days post inoculation. A high concordance of the binary results
(positives versus negatives) for the serostatus of the avian sera samples was observed between
wild type and chimera virus-based PRNT assay. There was a very good agreement (κ =0.92, p <
0.0005), between the wild type and the chimera regarding the serostatus of the avian sera. The
results furthered illustrated that the SINV/EEEV had 100% sensitivity and 90% specificity when
confirming avian sera samples. Both the wild type and the chimera virus were able to confirm all
20 presumptive positive samples, however, the chimera virus obtained an additional positive
result when the wild type virus confirmed it as negative (Table 1).

Table 1. Contingency table for the EEEV Avian sera samples. This table illustrates that both
the wild type and the chimeric virus confirmed all 20 presumptive positive samples, however, the
chimera virus obtained an additional positive result when the wild type virus confirmed it as
negative. Therefore, chimera virus has 90% sensitivity and 100% specificity when confirming
avian sera samples.
EEE-WT
Positive

EEE-WT
Negative

Total

EEE-Chi
(Positive)

20

1

21

EEE-Chi
(Negative)

0

9

9

20

10

30

Total
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Titer agreement of Avian Samples. The level of agreement between endpoint titers was
0.77 (p < 0.0005) with a positive correlation of 0.87 (Pearson’s correlation, p < 0.0005). The
overall endpoint titers for the chimera virus were comparable by 86% (26/30) to the wild type
titers. Out of the 20 avian sera samples that were confirmed positive with the wild type virus,
80% (16/20) were confirmed with an equivalent titer using the chimera virus. Two of the four
samples that differed had a 4-fold difference in titer, while the remainder had a 2-fold difference
(Table 2). A Wilcoxon signed rank test revealed that there was no statistical significance
between the titers of the wild type and the chimera virus and had a very small effect size (z = 0.184, r = 0.024, p = 0.854). For the negative avian sera samples, both the wild type and chimera
virus reported equivalent endpoint titers.
Serostatus of Clinical Samples. There was a 100% serostatus agreement
(κ = 1) between the wild type and chimera virus-based PRNT assays for the clinical human sera
samples. One of the positive samples yielded negative PRNT results for both the wild type and
chimera viruses, therefore there were a total of 19 confirmed positive samples and 11 negative
samples (Table 3). Sensitivity and specificity for confirming human sera was both 100%.
Titer agreement of Clinical Samples. An overall lower titer concordance for human
sera was observed between wild type and chimera virus-based PRNT assays. The chimera titers
were in fair agreement to the wild type titers (κ = 0.36; p < 0.0005), even though there was an
overall positive correlation of r = 0.96 (Pearson’s correlation, p < 0.0005). There were eight
samples (42%) where there was a 2 fold difference in titers, eight samples (42%) where there
was a 4-fold or more titer difference and three samples (16%) where the titers were the same
(Table 4). The Wilcoxon signed ranked test indicated that there was a statistical significance
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between the wild type and chimera titers and a medium effect size (z = -3.574, r = 0 .46, p <
0.0005).

Table 2. Comparison of neutralizing antibody titers in sera from infected sentinel chickens using
wt and chimera challenge EEEVs in PRNT90

Sample type
Avian
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

wt-EEEV

SINV/EEEV

>40
>40
>40
<10
>40
<10
>40
>40
1:20
1:20
<10
<10
<10
<10
<10
>40
1:20
>40
>40
>40
>40
1:10
>40
>40
>40
>40
>40
<10
<10
<10

>40
>40
>40
>40
1:10
<10
>40
>40
1:20
1:10
<10
<10
<10
<10
<10
>40
>40
>40
>40
>40
>40
1:10
>40
>40
>40
>40
>40
<10
<10
<10
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Table 3. Contingency table for the EEEV Clinical sera samples. This table shows that both
the wild type and chimera virus confirmed all twenty presumptive positive samples. One sample
confirmed as negative for both the wild type and chimera virus, therefore there was a total of 19
confirmed positive samples and 11 negatives. The chimera virus has 100% sensitivity and 100%
specificity when confirming avian sera samples.
EEE-WT
Positive

EEE-WT
Negative

Total

EEE-Chi
(positive)

19

0

19

EEE- Chi
(negative)

0

11

11

19

11

30

Total

West Nile Virus PRNT
Serostatus of Clinical Samples. Clinical samples used in the WNV assay were in
excellent agreement (κ = 1.00) between the chimera virus and the wild type virus regarding the
serostatus. The YF/WN chimera virus had a 100% sensitivity and specificity. Similar to the
EEEV PRNT, one of the 20 presumptive positive samples confirmed as negative for both the
wild type and chimera virus, therefore there were a total of 19 confirmed positive samples and 11
negatives (Table 5).
Titer agreement of Clinical Samples. The titers of clinical samples between the chimera
and the wild type obtained a positive correlation (r = 0.98, p < 0.0005, Pearson’s correlation),
yet, reached a fair measurement of agreement (k = 0.31; p < 0.0005). The chimera virus had 58%
(11/19) of the confirmed positive samples that were in 2-fold titer difference and 32% (6/19) that
were a 4-fold or more titer difference (Table 6). The Wilcoxon signed ranked test demonstrated
that there was a statistical significance between the wild type and chimera titers with a medium
effect size (z = -3.745, r = 0.48, p < 0.0005).
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Table 4. Comparison of neutralizing antibody titers in sera from diagnostic infected humans
using wt and chimera challenge EEEVs in PRNT90

Sample type
Human
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

wt-EEEV

SINV/EEEV

1:20480
1:1280
1:160
1:80
1:20480
1:320
<10
1:160
1:2560
1:10
<10
<10
<10
1:20480
1:10240
1:20
1:320
1:10240
1:160
1:640
1:80
1:40
1:20
<10
<10
<10
<10
<10
<10
<10

1:2560
1:1280
1:80
1:40
1:5120
1:20
<10
1:40
1:320
1:10
<10
<10
<10
1:10240
1:5120
1:10
1:320
1:1280
1:10
1:80
1:40
1:20
1:10
<10
<10
<10
<10
<10
<10
<10

30

Table 5. Contingency table for the WNV Clinical samples. This table demonstrates that both
the wild type and chimera virus confirmed all twenty presumptive positive samples. One sample
confirmed as negative for both the wild type and chimera virus, therefore there was a total of 19
confirmed positive samples and 11 negatives. The chimera virus has 100% sensitivity and 100%
specificity when confirming avian sera samples.

WNV-WT
Positive
WNVChi
(positive)
WNVChi
(negative)
Total

WNV-WT
Negative

Total

19

0

19

0

11

11

19

11

30

Table 6. Comparison of neutralizing antibody titers in sera from diagnostic infected humans
using wt and chimera challenge WNVs in PRNT90

Sample type
Human
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

wt-WNV

YFV/WNV

1:640
1:640
1:1280
1:1280
1:1280
1:2560
<10
1:320
<10
1:640
<10
1:2560
1:1280
1:2560
1:5120
1:2560
1:2560
1:80
1:80
1:40
1:2560

1:320
1:320
1:320
1:640
1:320
1:1280
<10
1:160
<10
1:320
<10
1:1280
1:1280
1:1280
1:640
1:1280
1:1280
1:80
1:20
1:20
1:320
31

22
23
24
25
26
27
28
29
30

1:40
<10
<10
<10
<10
<10
<10
<10
<10

1:10
<10
<10
<10
<10
<10
<10
<10
<10

Analyses of Prior Studies
Additional statistical analyses were performed on data from two studies that were
previously performed at the FDOH, BPHL-Tampa. One study standardized and validated the
West Nile Chimera in PRNT for the purpose of diagnosis avian serum samples. The sample
criteria and the number of positive and negative samples are the same as in this study. The
second study standardized and validated St. Louis encephalitis chimera in PRNT for diagnosis of
avian and clinical human serum samples. The sample criteria for both the avian and human
serum samples were the same as in this study.

West Nile Virus
Serostatus of Avian Samples. The YF/WNV chimera was able to neutralize in a like
manner to the wild type virus in the avian l sera samples Avian samples tested for WNV were in
excellent agreement (κ = 1.00) between the chimera virus and the wild type virus regarding the
serostatus. The YF/WN chimera virus had a 100% sensitivity and specificity.
Titer agreement of Avian Samples. The titer agreement between the chimera and the
wild type virus was 0.77 (p < 0.0005) with a positive correlation of 0.94 (p < 0.0005, Pearson’s
correlation). The overall endpoint titers for the chimera virus were comparable by 86% (26/30)
to the wild type titers. Out of the 20 avian sera samples that were confirmed positive with the
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wild type virus, 80% (16/20) were confirmed with an equivalent titer using the chimera virus. All
four samples had a 2-fold difference in titer. The Wilcoxon signed ranked test illustrated that
there was no statistical difference between the titers of the wild type and the chimera virus and
had a very small effect size (z = -0.368, r = 0.067, p= 0.713). For the negative avian sera
samples, both the wild type and chimera virus reported equivalent endpoint titers.

St. Louis Encephalitis Virus
Serostatus of Avian Samples. The chimera YF/SLE was able to neutralize in a like
manner to the wild type virus in the avian and clinical sera samples. The avian samples obtained
a good serostatus agreement between chimera and wild type virus (κ = 0.67). The YF/SLE
chimera had a specificity of 100%; however the sensitivity was 75%. In the wild type virusbased PRNT, five out of the 30 avian samples were detected as negative whereas, the samples
that were detective as positive in the chimera-based PRNT. As before, one of the 20 presumptive
positive samples confirmed as negative for both the wild type and chimera virus, therefore there
were a total of 19 confirmed positive samples and 11 negatives.
Titer agreement of Avian Samples. The avian titer agreement between the chimera and
the wild type virus was 0.67 (p < 0.0005) with a positive correlation of 0.69 (p < 0.0005,
Pearson’s correlation). The overall endpoint titers for the chimera virus were comparable by 83%
(25/30) to the wild type titers. Out of the 20 avian sera samples that were confirmed positive with
the wild type virus, 26% (5/19) were confirmed with an equivalent titer using the chimera virus.
A total of 32% (6/19) of the avian sera samples had a 4-fold titer difference and 16% (3/19)
obtained a 2-fold titer difference. The Wilcoxon signed ranked test illustrated that there was no
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statistical significant difference between the titers of the wild type and the chimera virus and had
a very small effect size (z = -0.64, r = 0.012, p = 0.949).
Serostatus of Clinical Samples. The human clinical samples tested for SLEV were in
excellent agreement (κ = 1.00) between the chimera virus and the wild type virus regarding the
serostatus. The YF/SLE chimera virus had a 100% sensitivity and specificity with respect to
human sera samples. There were a total of nine clinical samples that were tested which consisted
of four positive samples and five negative samples.
Titer agreement of Clinical Samples. The titer agreement for SLEV clinical sera
samples were fair between the chimera and the wild type virus (κ = 0.38; p < 0.0005) with a
positive correlation of 0.97 (p < 0.0005). The overall endpoint titers for the chimera virus were
77% (7/9) comparable to the wild type titers. Out of the four clinical sera samples that were
confirmed positive with the wild type virus, 50% (2/4) were confirmed with an equivalent titer
using the chimera virus. A total of 25% (1/4) of the clinical sera samples had a 4-fold titer
difference and 25% (1/4) obtained a 2-fold titer difference. The Wilcoxon signed ranked test
illustrated that there was no statistical significant difference between the titers of the wild type
and the chimera virus and had a moderate effect size (z = -1.342, r = 0.24, p = 0.183).
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Chapter Five: Discussion
Assessment of the Serostatus Outcomes
The purpose of this study was to assess and validate the use of chimera viruses in PRNT
for diagnostic purposes for the state of Florida. The PRNT results for EEEV, WNV, and SLEV
chimeras were comparable to their respective counterpart wild type viruses for the avian and
clinical serum samples. The avian sera samples that were tested for EEEV antibodies had a 92%
serostatus agreement between the wild type virus and the chimera virus. The 92% serostatus
agreement was due to one additional positive sample that the chimera resulted than the wild type
virus. For the EEEV clinical serum samples, there was a 100% serostatus agreement between the
wild type and the chimera virus. There was a 100% serostatus agreement between the wild type
virus and the chimera virus for both avian and clinical samples tested for WNV antibodies. The
YF/SLE chimera performed analogous to wild type virus. The serostatus agreement for the avian
samples was 67%. The decrease in serostatus agreement may be attributed to pipetting errors that
could have occurred while creating the viral-serum mixture. Nonetheless, there were no errors
that caused a significant impact to induce a change in results. However, there was a 100%
serostatus agreement between the wild type virus and the chimera virus for the clinical samples
tested for SLEV antibodies.
The serostatus results indicate that the non-EEEV, non-WNV, and non-SLEV
neutralizing antibodies in the sera reacted effectively to both the wild type virus and the chimera
virus for each virus, respectively. Moreover, antibody recognition and neutralization are specific
to the EEEV, WNV, and SLEV structural proteins of the chimera virus, respectively (Johnson et
al., 2011). The observed outcome confirms that the avian and clinical sera did not contain
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antibodies against alphavirus (i.e. SINV) nonstructural proteins and flavivirus (i.e. YFV)
nonstructural proteins. Therefore, there was no evidence that SINV or YFV nonstructural protein
genes present in each chimera influenced serological results (Johnson et al., 2011).

Assessment of the Titer Agreements
A notable difference in PRNT endpoint titers were detected between the wild type and
chimera viruses for EEEV, WNV, and SLEV antibodies among avian and clinical samples. In all
of the cases, the titer differences ranged between two-fold to four-fold or greater. However, the
difference in titers is not uncommon.
Comparison of Studies. Several studies have also illustrated differences in titers
between the chimera and the wild type virus. Johnson et al. (2011) reported that the log titers of
antibodies to the EEEV wild type were on average 1.3 times greater than the log titers to the
antibodies of the chimera. Haolin et al. (2007) also displayed that there was a one to two-fold
difference in titers between the parental and the chimera virus. Komar, Langevin, & Monath
(2009) documented that the titers of the WNV wild type was greater by four-fold or more when
compared to the chimera. Pugachev et al. (2004) demonstrated that the titers for the SLE chimera
virus were up to four times lower than the wild type virus.
Hypotheses for Difference in Titer Agreements. The reason behind the differences in
titers is not well understood. One possible reason for this difference is that the construct of the
chimera appears to improperly bind to all the receptors of the antibodies due to conformational
changes in the chimera virus envelope, thus decreasing the sensitivity, in comparison to the wild
type that may bind to several receptors creating a greater sensitivity (Johnson et al., 2011;
Komar, Langevin, & Monath, 2009). Theoretically, differences in titer agreements should be
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very minute since the structural protein compositions of these chimera viruses should be
analogous to the wild type (Johnson et al., 2011). One probable explanation for the difference
may be that a conformational change in the chimera virus envelope could have lowered the
avidity or blocked the receptors that recognize certain immunoglobulins (Komar, Langevin, &
Monath, 2009).
Another possible explanation for the reduction in titer sensitivity is that the RNA
interactions among the proteins impact the structure of the viruses in such a way to induce a
slight change in conformation in the chimera viruses that results in titer differences (Johnson et
al., 2011). The conformational change may be due to abnormal interactions between the vaccine
portion (or SINV in the case of EEE chimera) of the chimera RNA genome and the viral proteins
(Johnson et al., 2011; Komar, Langevin, & Monath, 2009). In order to test these hypotheses, a
structural study of the chimera viruses and the corresponding wild type virus would have to be
conducted via cryo-electron microscopy (Johnson et al., 2011).
Furthermore, the differences within the titers could occasionally result in a sample that is
confirmed as weakly positive (low titer) using the wild type virus, whereas the sample would be
confirmed as negative using the chimera virus (Johnson et al., 2011). However, this
seroconversion is also dependent upon the time of collection of the sera specimens. Sera samples
that are collected too early or too late with regards to onset of symptoms can cause the titers to
fall below the lowest titer of quantification using the chimera viruses and result in false negatives
(Beaty, Calisher, & Shope, 1995; Johnson et al., 2011). Nevertheless, naturally occurring
infections typically result in titers well above the lower titer of quantification and therefore
should not yield false negatives. Moreover, the relatively small possibility of false negatives
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occurring is override by the enhanced safety component of the chimera viruses and the reduction
in regulatory requirements for using chimeras (Jonshon et al., 2011).
Ratio of Kappa Values. Interestingly, upon observing the differentiation among titer
agreements between the chimera viruses and the wild type viruses, a pattern was noticed. The
titers obtained from the avian sera samples had a higher concordance to the titers of the wild type
virus when compared to the titers obtained from the clinical sera samples. The variation in titer
agreements among the avian and clinical sera samples was illustrated amid the EEE, WN, and
SLE chimera viruses.
The titers of avian sera that were tested for EEEV were typically 2.14 times more in
agreement with wild type titers than the clinical sera. Again, the titer agreement for the EEEV
antibody positive avian sera samples was 0.77, whereas the titer agreement for the EEEV
antibody positive clinical samples was 0.36. Analogous to EEEV, the titers of the avian sera
sample were, on average, 2.48 times more in agreement with the wild type virus titers than the
clinical sera for WNV. To reiterate, the titer agreement for the WNV antibody positive avian sera
samples was 0.77, meanwhile the clinical sera obtained a titer agreement of 0.31. The
comparison of avian to clinical titer agreements for SLEV was not as drastic as EEEV and
WNV. For SLEV, the avian titer agreement for positive sera samples was generally 1.76 times
more in agreement with the wild type virus titers than the clinical sera. The titer agreement for
the avian sera samples was 0.67; however, the titer agreement for the clinical sera was 0.38.
Comparison of Studies. This pattern has also been cited in other studies as well. Komar,
Langevin, & Monath (2009) study demonstrated that the WNV titer agreement among avian
samples was 0.86, whereas the titer agreement for the equine samples was only 0.45. Johnson et
al. (2011) also displayed similar titers between the wild type and the EEE chimera virus among
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the murine samples (mice had less than an 8-fold titer difference), but obtained varying titers
among the equine (equines had a 4 to 16 fold titer difference) and the clinical samples (humans
had a 4 fold or greater titer difference) within their tables. In addition, there are other studies that
illustrate a variation among interspecies in humoral immune responses such as mice and humans
and mice and horses (Komar, Langevin, & Monath, 2009; Oliphant et al., 2007, Sanchez et al.,
2007).
Hypothesis for Difference in Kappa Values. One likely explanation for the
differentiation of titer agreements between avian sera samples and clinical sera samples is that
the supplement added to the diluent that is used throughout PRNT does not support clinical or
equine sera samples and therefore yields a lower sensitivity than the avian or murine sera
samples when performing PRNT with the chimera virus (Komar, Langevin, & Monath, 2009;
Even, Sandusky, & Barnard, 2006). In this study, as well as the several studies mentioned above,
the supplement added to the diluent of choice was Fetal Bovine/Calf Serum. Animal sera
typically consist of prions, mycoplasmas, fungi, bacteria, hormones and endocrines, and viruses.
Fetal Bovine/Calf Serum has several facets that can hinder the results of an experiment (Even,
Sandusky, & Barnard, 2006; Jochems, van der Valk, Stafleu, & Baumans, 2002). Another
possible explanation for the difference in titer agreements between avian and clinical sera
samples has to do with how the test is performed. Although, the media is poured or vacuumed
off of the monolayer of cells, the cells are never washed with a buffer (i.e. Phosphate Buffer
Saline, PBS). In cell culture, it is highly important to wash with PBS so that the pH and the
osmolality of the cells can be maintained. The buffer also aids in the removal of inhibiting
growth factors found within FBS/FCS (Dulbecco & Vogt, 1954). Furthermore, there is an
additional 50 µl of FBS/FCS supplemented media that remains on the monolayer of cells.
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Commercially purchased FBS/FCS has been reported to be between 20% to 50% virus
positive. Removal of these viral contaminants can be difficult and costly. Theses viral
contaminants can introduces adverse factors that can potentially skew the outcome of
experiments performed, such as PRNT. Another factor that can influence the results of an assay
is the FBS/FCS ability to interfere with genotypic and phenotypic cell stability (Even, Sandusky,
& Barnard, 2006). In addition, commercially purchased serum can vary quantitatively and
qualitatively in their composition and therefore create lot-to-lot variable that may produce
adverse outcomes. Moreover, serum-supplemented media may lack the ability to support the
growth of specific cell types and thus hinder the performance cell-based assays (Brunner, Frank,
Appl, Schoffl, Pfaller, & Gstraunthaler, 2010).
Overall, animal sera introduce a wide variety of unknown variables into tissue culture
(Brunner, Frank, Appl, Schoffl, Pfaller, & Gstraunthaler, 2010; Jochems, van der Valk, Stafleu,
& Baumans, 2002). The disadvantages that animal sera supplement introduces—in conjunction
with the reduced sensitivity of the chimera viruses creates several possibilities that may explain
the difference in titer variation between wild type virus and chimera virus in addition to avian
and clinical sera samples. The animal serum supplement may be a factor in the chimera’s ability
to properly bind to the antibody in order to illicit a similar response to the wild type virus.
Antibodies within the animal serum could bind to chimera instead of the antibodies in the
specimen of interest (Brunner, Frank, Appl, Schoffl, Pfaller, & Gstraunthaler, 2010; Komar,
Langevin, & Monath, 2009).
With these possibilities in mind, alternative supplements, such as serum-free media, for
equine and clinical sera samples should be considered and tested to observe whether the titer
agreements become more similar to the wild type virus compared to avian and murine sera
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samples. The different supplements may make a difference in sensitivity for the chimeras and
could enhance plaque morphology in PRNT (Appendix G). Furthermore, washing the plate of
monolayer cells with PBS prior to inoculation may optimize the performance of the chimera
viruses for both avian and clinical sera samples.

Limitations of the Study
There were a few limitations to performing PRNT. One of the primary limitations to
performing the validation of the SINV/EEEV chimera was the limited quantity of clinical
samples that were EEEV antibody positive. Since EEE is a rare arboviral infection and there
were only thirteen positive samples that could be retrieved, additional samples had to be
contrived in order to meet the qualifications under CLIA regulations in validating an assay,
which recommends a minimum of 20 samples for performing validations. In addition, during one
of the EEEV PRNT validations, phenol red was accidentally used instead neutral red as the
viable dye. Though the incorrect dye was used, plaques were still visible enough to read and
count the plaques and therefore did not affect the outcome of the assay.
Another limitation was that all the chimera viruses had to be titrated in order to be in the
correct range of working concentrations for the challenge virus. Occasionally, the titration had to
be performed several times in order to yield optimal results. Furthermore, some of the chimera
viruses had to be cultured prior to performing the viral titrations. This caused a delay in
validating chimera viruses, but did not hinder the results or the performance of the assay.
Another predominate limitation that manifested, occurred during the quantification of
plaques. The morphology of the plaques varied for each wild type virus and their counterpart
chimera virus. Some viruses did not yield clear and distinct plaques, and therefore caused
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difficulty in quantitating the number of plaques. Furthermore, there were problems that occurred
with certain equipment such as the incubators. One of the incubators was leaking CO2 which
caused a disruption in the amount of humidity necessary to keep the cells and plaques from
drying out. This caused a few of the plates to produce a smaller size plaque. Nevertheless, the
plaques were visible and clear enough to read the plates and therefore had no effect on the
results. Also, two different titer calculations had to be used when assessing the titers for avian
samples that were performed using and endpoint of 95% for PRNT, instead of using the endpoint
titer of 90% for PRNT that is frequently used for clinical samples. Therefore, the titer
calculations had to be recalculated for avian clinical samples.

Conclusion of the Study
All in all, the findings of this study will provide the opportunity for public health
laboratories that do not have a high-level biosafety facility or Select Agent certification to
perform confirmatory diagnostic testing and provide a safer environment for laboratory
personnel to perform arboviral PRNT (Komar, Langevin, & Monath, 2009). These chimeras will
allow PRNT to be performed in a BSL-2 biocontainment laboratory. The use of chimera viruses
serves as a sufficient surrogate diagnostic reagent in place of the wild type virus for PRNT
assays when performed with nonhuman vertebrate sera and clinical sera, with the caveat of the
chimera viruses having a slight reduction in sensitivity for weakly positive sera samples with low
levels of neutralizing antibodies (Komar, Langevin, & Monath, 2009).
Furthermore, these findings will provide other public health laboratories that perform
PRNT with more insight and understanding about chimera viruses in serological assays. The
information gathered should inspire the desire to optimize the PRNT assay for each public health
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laboratory that performs this assay. Alternative laboratory techniques to be used for diagnostic
purposes that would have the potential to replace the classical PRNT assay are encouraged.
Overall, arboviral surveillance and prevention will be greatly enhanced with the use of these
chimera viruses.
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Chapter Six: Future Improvements and Research
Future Improvements
Problematic Encounters. Even though PRNT is a gold standard confirmatory test, there
is a lack of standardized protocols on how to properly perform PRNT. For this reason, there
exists significant variation in diagnostic results across laboratories that perform this assay.
Although there are only a few states within the U.S. that perform PRNT, every laboratory has
their own “in house” protocol. Each laboratory uses their own cell line, media supplements, and
varying types of vital dyes. All of these differences can drastically affect the outcome of the
assay. Furthermore, variability exists within the methodology of counting plaques which can lead
to discrepancies in results (both within and between laboratories).
These discrepancies can result in one patient sample having a strong titer for the virus in
one laboratory, whereas another laboratory may view the serum sample as negative or weakly
positive. For example, all of the laboratories that participated in the CDC 2017 Arbovirus
Proficiency had a vastly different starting and ending titers in their assay. This resulted in
drastically different titers for the unknown samples. With the numerous possibilities for
discrepancy and variability, the state and local public health laboratories need more guidance and
structure for performing PRNT for diagnostic purposes.
Possible Solution. With these variances taking place, future improvements to optimize
and standardize the assay should be considered. The CDC should host a training course for
PRNT in order to ensure that there is a level of standardization in how this technique is to be
performed. ArboNet or another arbovirus surveillance division of the CDC should consider
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developing a standardize protocol in addition to hosting a PRNT training course for those who
perform diagnostic and surveillance PRNT.

Future Research
Nonetheless, there are other alternatives assays to PRNT that are less stringent and
tedious to perform that have a more standardize protocol. One alternative to PRNT is the
Fluorescence-based plaque reduction micro neutralization assay (PRMN). This assay consists of
visual and automated readouts using enhanced green fluorescent protein that is expressed within
recombinant bio-engineered viruses (Fujino et al., 2007; Duprex, McQuaid, Hangartner, Billeter,
& Rima, 1999). The assay is requires less time to complete and is less labor-intensive and is also
less expensive than the classic PRNT. The assay takes only two days to complete unlike seven
days and uses a micro format. The PRMN has been tested and reported to yield similar values as
the gold standard PRNT, and therefore should be considered as an alternative to PRNT
(Haralambieva, Ovsyannikova, Vierkant, & Poland, 2008).
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Appendix A
Plaque Morphology
Eastern Equine Encephalitis Plaque formation. Plaques were visible upon two days
post inoculation. The morphology of the plaques for both the wild type and the chimera were
typically considerably large in size, very clear to see, and were evenly distributed among the
tissue culture plate. However, due to the considerably large plaque size, the border of the plaques
were not as defined which made it slightly difficult to determine where a plaque started and
where it ended. Nonetheless, this was consistent among the plates for both the wild type and
chimera and therefore did not affect the plaque count. Both the wild type and the chimera seem
to grow fast which indicates how virulent the virus can be.
West Nile Virus Plaque Formation. Plaques were made visible for the wild type
approximately two to three days post inoculation, whereas the plaques for the chimera virus
typically were seen by day two post inoculation of the monolayer of cells. The morphology of
the plaques for both the wild type and chimera virus were moderate in size, clear to see, however
the border of the plaques were not as defined. The WNV chimera and the WNV wild type virus
are not as virulent as the EEE chimera and the EEE wild type virus. There was an even
distribution of plaques placed about the plate.
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